Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2012 - 2026)

Jazz Pharmaceuticals' Non-Current Deferred Tax Liability history runs 15 years deep, the most recent figure standing at $547.7 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 18.35% year-over-year to $547.7 million in Q1 2026; TTM through Mar 2026 was $547.7 million, a 18.35% decrease from a year earlier, with the FY2025 full-year figure at $594.5 million, down 12.15% from the prior year.
• Non-Current Deferred Tax Liability eased to $547.7 million in Q1 2026 per JAZZ's latest filing, from $594.5 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $1.2 billion in Q1 2022 and bottomed at $547.7 million in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $809.7 million (2024), against an average of $818.0 million.
• Biggest YoY gain for Non-Current Deferred Tax Liability was 1011.84% in 2022; the steepest drop was 29.76% in 2022.
• Year by year, Non-Current Deferred Tax Liability stood at $944.3 million in 2022, then declined by 10.23% to $847.7 million in 2023, then slipped by 20.17% to $676.7 million in 2024, then declined by 12.15% to $594.5 million in 2025, then declined by 7.87% to $547.7 million in 2026.
• Per Business Quant, the three latest JAZZ Non-Current Deferred Tax Liability figures stand at $547.7 million (Q1 2026), $594.5 million (Q4 2025), and $629.0 million (Q3 2025).